{"analyses":[{"ciLowerLimit":"0.54","ciPctValue":"95","ciUpperLimit":"0.89","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.004","paramType":"Hazard Ratio (HR)","paramValue":"0.70","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6"},{"groupId":"OG001","value":"15.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"702"}],"units":"Participants"}],"description":"Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.","groups":[{"description":"Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline up to data cut-off (up to approximately 5 years and 2 months)","title":"Time to Next Anti-Lymphoma Treatment (Overall Study Population)","type":"SECONDARY","unitOfMeasure":"percentage of participants with event"}